Difference between revisions of "Motesanib (AMG-706)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGFR inhbitors" to "Category:VEGFR inhibitors") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 7: | Line 7: | ||
# Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. [http://www.nejm.org/doi/full/10.1056/NEJMoa075853 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18596272 PubMed] | # Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. [http://www.nejm.org/doi/full/10.1056/NEJMoa075853 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18596272 PubMed] | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 23:02, 13 June 2018
Mechanism of action
From the NCI Drug Dictionary: The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors
Preliminary data
Thyroid cancer
- Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. link to original article PubMed